Critical Insights From Calliditas Therapeutics Analyst Ratings: What You Need To Know
Calliditas Therapeutics Analyst Ratings
Citi Downgrades Calliditas to Neutral, Cites Takeover Offer
Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39
Stifel Downgrades Calliditas Therapeutics to Hold From Buy, Cuts Price Target to $40 From $55
Calliditas Therapeutics Analyst Ratings
Asahi Kasei's Acquisition of Calliditas Therapeutics: A Hold Rating With Revised Price Target
Analysts Offer Insights on Healthcare Companies: Allakos (ALLK), Calliditas Therapeutics (CALT) and Clene (CLNN)
Kepler Capital Remains a Buy on Calliditas Therapeutics (CALT)
Calliditas Therapeutics Analyst Ratings
Buy Rating Affirmed for Calliditas Therapeutics Amid Strong Growth and Expanding Market Opportunities
Analysts Are Bullish on Top Healthcare Stocks: Calliditas Therapeutics (CALT), Aclarion, Inc. (ACON)
Stifel Nicolaus Sticks to Its Buy Rating for Calliditas Therapeutics (CALT)
Buy Rating Affirmed for Calliditas Therapeutics Amid Positive Market Trends and Upcoming Catalysts
Analysts Offer Insights on Healthcare Companies: Calliditas Therapeutics (CALT), AK Medical Holdings Ltd. (HK:1789) and Consun Pharmaceutical Group Ltd. (Frankfurt: DE:C1P)
Calliditas Therapeutics Analyst Ratings
Calliditas Therapeutics: Strong Sales and FDA Approval Propel Buy Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), Calliditas Therapeutics (CALT) and Sanofi (OtherSNYNF)
Kepler Capital Sticks to Its Buy Rating for Calliditas Therapeutics (CALT)
Calliditas Therapeutics (CALT) Gets a Buy From Stifel Nicolaus